Cancer biologists at Weill Cornell Medicine have been awarded a 2021 Top 10 Clinical Research Achievement Award from the Clinical Research Forum for their study last year describing a highly sensitive blood test for monitoring cancer progression and relapse.
Dr. Dan Landau, an associate professor of medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, has been awarded a four-year, $600,000 Distinguished Scientist grant by the Sontag Foundation to study the diversity of cell types within brain cancers called gliomas.
Five Weill Cornell Medicine investigators have received funding from the Chan Zuckerberg Initiative (CZI) for their research in inflammation and neurodegenerative disorders.
Dr. Dan Landau, an associate professor of medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, has been named a 2020 Vallee Scholar by the Vallee Foundation.
A DNA-sequencing strategy powered by machine learning may pick up even very low levels of tumor DNA in blood samples, potentially enabling the early detection of cancer recurrence after surgery or other treatments, according to a study led by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC).
Gene mutations that are thought to be very early events in the development of leukemias and other blood disorders appear to set the stage for malignancy by increasing the production of certain types of blood cells at the expense of others.
A set of powerful laboratory and computational techniques developed by scientists at Weill Cornell Medicine, the New York Genome Center (NYGC) and the Broad Institute will enable investigators to map the capacity of tumors to develop resistance to drugs and drug combinations.
A new technology devised by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC) enables the measurement of gene mutations and their effects on gene activity within individual cancer cells biopsied from patients.
A powerful new set of scientific tools developed by Weill Cornell Medicine and New York Genome Center (NYGC) researchers enables them to track the molecular evolution of cancers.
The second annual Dean’s Symposium on Opportunities for Entrepreneurship and Academic Drug Development highlighted the resources available to Weill Cornell Medicine investigators to help them turn their research findings into new treatments and therapies for patients.
Dr. Dan Landau has received a New Innovator Award from the National Institutes of Health for his research on how tumor cells evolve and acquire new mutations to evade cancer therapies.
A type of stem cell newly discovered by Weill Cornell Medicine and NewYork-Presbyterian investigators is responsible for growing and healing the hard, outer surface of bone.
Dr. Dan Landau, an assistant professor of medicine and of physiology and biophysics at Weill Cornell Medicine, and a core faculty member of the New York Genome Center, has been awarded the Pershing Square Sohn Prize for Young Investigators in Cancer Research to support his work studying cancer evolution.
Ongoing monitoring for genetic changes in chronic lymphocytic leukemia (CLL) during targeted treatment may allow clinicians to adjust patients’ treatments as the cancer evolves, according to a study in Nature Communications led by Weill Cornell Medicine and New York Genome Center scientists.
